By Drug Target Review2025-11-13T13:00:14
Pioneering circular RNA could redefine what the future of gene therapy looks like. Erik Digman Wiklund, CEO of Circio, shares how his company’s platform is enhancing gene expression and tackling toxicity challenges through smarter design and scientific collaboration.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-30T09:54:00Z
2025-08-05T13:42:00
Sponsored by ICON plc., By Drug Target Review
2023-01-04T16:08:55
Sponsored by Sartorius Incucyte® Live-Cell Analysis System
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2024-02-06T08:57:06
Sponsored by bit.bio
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
Site powered by Webvision Cloud